Publications by authors named "P S Ahmed"
Introduction: Ceftazidime-avibactam (CAZ-AVI) has emerged as a promising treatment option for Gram-negative infections, particularly those caused by CAZ-Non-Susceptible (NS) pathogens. This systematic review and meta-analysis aim to assess the efficacy and safety of CAZ-AVI in these challenging infections.
Methods: We systematically queried EMBASE, Cochrane CENTRAL, and PubMed/Medline for studies published until September 15, 2024.
Article Synopsis
- Rural areas face higher rates of substance use disorder (SUD) and stigma, which affects treatment access.
- A comparative study between rural Ohio (2020) and South Dakota (2022-2023) highlights significant differences in attitudes towards SUD, showing South Dakotans are more likely to view addiction as an illness.
- The findings suggest that acknowledging SUD as an illness reduces stigma and increases support for harm reduction strategies, emphasizing the need for targeted anti-stigma campaigns to enhance treatment-seeking behaviors in rural communities.
Article Synopsis
- Primary leiomyosarcoma in bone is a rare tumor that mainly occurs in older adults and may be a metastasis; it requires careful evaluation and broad surgical excision as treatment.
- A case study describes a 50-year-old man with a painful mass in his left wrist, diagnosed with primary leiomyosarcoma of the distal ulna and treated with wide resection and stabilization.
- This type of tumor, although uncommon, should be considered when diagnosing lytic aggressive bone lesions in middle-aged patients, with surgery being the primary treatment method.
Background Autism spectrum disorders (ASDs) are a collection of neurological, psychological, and developmental anomalies that manifest in early life, affecting individuals across all racial, cultural, and socioeconomic groups. Its prevalence has grown significantly over the past 20 years. Exposure to digital devices has increased alongside the rise in ASD prevalence.
View Article and Find Full Text PDFOsteosarcoma is the most common malignant bone tumor, primarily affecting children and young adults. For these young patients, the current treatment options for osteosarcoma impose considerable constraints on daily life with significant morbidity and a low survival rate. Despite ongoing research efforts, the 5-year survival rate of first-diagnosed patients without metastases has not changed in the past four decades.
View Article and Find Full Text PDF